Bullfrog AI Holdings Inc. (NASDAQ:BFRG) Stock Short Interest Jumps 626.5%

Bullfrog AI Holdings Inc. (NASDAQ:BFRG) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 739,209 shares, a growth of 626.5% from the September 15th total of 101,743 shares. Based on an average daily trading volume, of 24,317,264 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.7% of the company’s stock are short sold.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Weiss Ratings raised Bullfrog AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Zacks Research raised Bullfrog AI to a “hold” rating in a report on Friday, June 26th. Finally, Wall Street Zen raised shares of Bullfrog AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bullfrog AI presently has a consensus rating of “Reduce”.

Insider Activity

In related news, CFO Joshua Blacher bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were acquired at an average price of $0.53 per share, for a total transaction of $26,500.00. Following the completion of the acquisition, the chief financial officer owned 65,000 shares of the company’s stock, valued at approximately $34,450. The trade was a 333.33% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Vininder Singh bought 75,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were purchased at an average price of $0.60 per share, for a total transaction of $45,000.00. Following the completion of the acquisition, the chief executive officer owned 2,442,446 shares of the company’s stock, valued at $1,465,467.60. The trade was a 3.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 14.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bullfrog AI

A hedge fund recently bought a new position in Bullfrog AI stock. J. Safra Sarasin Holding AG bought a new stake in shares of Bullfrog AI Holdings Inc. (NASDAQ:BFRG) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 113,720 shares of the company’s stock, valued at approximately $191,000. J. Safra Sarasin Holding AG owned approximately 0.90% of Bullfrog AI at the end of the most recent reporting period. Institutional investors and hedge funds own 0.96% of the company’s stock.

Bullfrog AI Price Performance

Shares of NASDAQ BFRG opened at $0.65 on Friday. The company has a 50 day simple moving average of $0.57 and a 200 day simple moving average of $0.69. Bullfrog AI has a 1 year low of $0.43 and a 1 year high of $1.96. The firm has a market cap of $11.98 million, a PE ratio of -1.40 and a beta of -2.73.

Bullfrog AI (NASDAQ:BFRG) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. As a group, research analysts anticipate that Bullfrog AI will post -0.37 earnings per share for the current fiscal year.

Bullfrog AI Company Profile

BullFrog AI Holdings, Inc is a technology company focused on applying artificial intelligence and machine learning to the medical and healthcare industries. The company develops tools intended to help organizations analyze complex biomedical and clinical data, identify patterns, and support research and decision-making.

Its primary platform, bfLEAP, is designed to provide advanced data analysis and predictive analytics for pharmaceutical and biotechnology companies, medical institutions, and other healthcare-related organizations.